Rameen Beroukhim
机构: Dana-Farber Cancer Institute, Harvard Medical School
主页: beroukhimlab.org
每年引用次数
引用次数
引用: 174,809
H-指数: 155
I10-指数 : 284
出版物: 581
[Correspondence] Breast-cancer stromal cells with TP53 mutations
A. Patocs , E.W. Thompson , S.C. Lebret , L. Zhang
The New England Journal of Medicine
2008
Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients.
J. Bartolomeo , A. D. Norden , J. Drappatz , A. S. Ciampa
Journal of Clinical Oncology 28 2043 -2043
4
2010
Phase I Trial of Vandetanib Plus Sirolimus in Adults with Recurrent Glioblastoma (P04.180)
M. Chheda , P. Wen , F. Hochberg , A. Chi
Neurology 78
2012
Interim Analysis of a Randomized Placebo-Controlled Pilot Trial of Armodafinil for Fatigue in Patients with Malignant Gliomas Undergoing Radiotherapy with or without Standard Chemotherapy Treatment (P07.104)
S. Hammond , J. Drappatz , E. Lee , A. Muzikansky
Neurology 78 ( Meeting Abstracts 1) P07.104 -P07.104
2012
Preliminary Data from a Multicenter, Phase II, Randomized, Non-Comparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly-Diagnosed Glioblastoma (GBM) (S45.006)
E. Lee , T. Batchelor , T. Kaley , D. Schiff
Neurology 78
2012
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
E. Q. Lee , D. A. Reardon , D. Schiff , J. Drappatz
Neuro-oncology 17 ( 6) 862 -867
66
2015
EPIGENETIC TARGETING OF HEDGEHOG PATHWAY TRANSCRIPTIONAL OUTPUT
Y.-J. Cho , Y. Tang , S. Schubert , M. Willardson
Neuro-oncology 16
2014
BM-07GENOMIC CHARACTERIZATION OF BRAIN METASTASES REVEALS BRANCHED EVOLUTION AND METASTASIS-SPECIFIC MUTATIONS
P. Brastianos , S. Carter , S. Santagata , A. Taylor-Weiner
Neuro-oncology 16
1
2014
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
L. A. Ramkissoon , P. M. Horowitz , J. M. Craig , S. H. Ramkissoon
Proceedings of the National Academy of Sciences of the United States of America 110 ( 20) 8188 -8193
143
2013
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene
G. P. Dunn , H. W. Cheung , P. K. Agarwalla , S. Thomas
Proceedings of the National Academy of Sciences of the United States of America 111 ( 3) 1102 -1107
38
2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
A. D. Norden , K. L. Ligon , S. N. Hammond , A. Muzikansky
Neurology 84 ( 3) 280 -286
53
2015
Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.
C. Lu-Emerson , A. D. Norden , J. Drappatz , E. C. Quant
Journal of Neuro-oncology 104 ( 1) 287 -291
54
2011
Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
J. Drappatz , E. Q. Lee , S. Hammond , S. A. Grimm
Journal of Neuro-oncology 107 ( 1) 133 -138
65
2012
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
M. L. Sos , S. Fischer , R. Ullrich , M. Peifer
Proceedings of the National Academy of Sciences of the United States of America 106 ( 43) 18351 -18356
285
2009
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
R. Beroukhim , G. Getz , L. Nghiemphu , J. Barretina
Proceedings of the National Academy of Sciences of the United States of America 104 ( 50) 20007 -20012
1,185
2007
Phase II study of dose-intense temozolomide in recurrent glioblastoma.
S. Hammond , A. D. Norden , G. J. Lesser , J. Drappatz
Journal of Clinical Oncology 29 2038 -2038
9
2011
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Samantha N Hammond , Andrew D Norden , Jan Drappatz , Surasak Phuphanich
Journal of Clinical Oncology 29 2040 -2040
12
2011
A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG).
J. Drappatz , J. J. Raizer , D. Schiff , A. S. Chi
Journal of Clinical Oncology 29 2050 -2050
7
2011
Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM).
E. C. Quant , T. Batchelor , A. B. Lassman , D. Schiff
Journal of Clinical Oncology 29 2069 -2069
9
2011
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
H. B. Salvesen , S. L. Carter , M. Mannelqvist , A. Dutt
Proceedings of the National Academy of Sciences of the United States of America 106 ( 12) 4834 -4839
246
2009